Abeona TherapeuticsABEO
Market Cap: $240M
About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
Employees: 84
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,960% more call options, than puts
Call options by funds: $5.78M | Put options by funds: $189K
200% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
36% more capital invested
Capital invested by funds: $105M [Q1] → $143M (+$37.5M) [Q2]
29.14% more ownership
Funds ownership: 52.93% [Q1] → 82.06% (+29.14%) [Q2]
14% less funds holding
Funds holding: 56 [Q1] → 48 (-8) [Q2]
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 170%upside $15 | Buy Reiterated | 14 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 170%upside $15 | Buy Reiterated | 12 Jul 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 170%upside $15 | Buy Initiated | 3 Jul 2024 |
Financial journalist opinion
Based on 5 articles about ABEO published over the past 30 days